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Summary The standard management of primary gastric lymphoma (PGL) (stage 11) has not been established despite the use of various
treatment modalities. The present prospective trial of combined surgery and chemotherapy for the treatment of PGL (stage 11) included 25
consecutive patients treated between July 1978 and December 1993. Twenty-one patients were treated with total gastrectomy and four with
partial gastrectomy; this was followed by post-operative chemotherapy with m-VEPA (vincristine, cyclophosphamide, prednisolone and
doxorubicin), followed by consolidation chemotherapy with VEMP (vindesine, cyclophosphamide, methotrexate and prednisolone) or VQEP
(vindesine, carbazilquinone, cyclophosphamide and prednisolone). Twenty-one of the 25 patients who completed post-operative
chemotherapy were free of relapse 26-203 (median 94) months afterthe gastrectomy. Ofthe fourpatients who did notcomplete the projected
chemotherapy, two relapsed and died of lymphoma. Another patient with recurrent lymphoma died in an accident, and the fourth patient was
in remission at 54 months after surgery. The post-operative overall and disease-free survival rates at 10 years for the 25 evaluable patients
were 81.6% and 92.0% respectively. Major surgical complications and treatment-related death after chemotherapy were not observed. PGL
(stage 11) appears to be curable when treated with gastrectomy and adjuvant chemotherapy.
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The stomach is the most common site of extranodal lymphomas,
accounting for about 24% of cases (Freeman et al, 1972).
Although localized (stage I and II) primary gastric lymphoma
(PGL) has been treated by various modalities, including surgery
(Shiu et al, 1982), chemotherapy (Maor et al, 1984: Salles et al,
1991), surgery plus radiotherapy (Shiu et al, 1982; Gospodarowicz
et al, 1983; Taal et al, 1993), surgery plus chemotherapy (Paulson
et al, 1983; Sheridan et il, 1985; Shepherd etal, 1988; Bellesi etal,
1989; Pasini et al, 1994) and radiotherapy plus chemotherapy
(Burgers et al, 1988; Dragosics et al, 1985, Maor et al, 1990;
Tondini et al, 1993), the best management for this disease is still
unclear.
During the last two decades, many combination chemotherapy
regimens including doxorubicin (McKelvey et al, 1976; Rodriguez
et al, 1977; Skarin et al, 1977) were developed for patients with
aggressive non-Hodgkin's lymphoma (NHL), and the treatment of
advanced-stage NHL patients has been one ofthe major successes
ofcancer therapy.
A combination chemotherapy known as VEM(N)P [vincrin-
stine, cyclophosphamide (Endoxan), 6-mercaptopurine or procar-
bazine, and prednisolone (Sakai, 1976)] was regarded in Japan
around 1975 as a standard regimen for patients with advanced
malignant lymphoma. At that time, we treated two patients with
PGL (stage II) with a 3-year cyclic VEMP therapy after surgical
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resection; they survived without relapse for over 9 years
(Takenaka et al, 1981).
The Japanese Lymphoma Study Group began a prospective
study ofadvanced NHL patients treated with VEPA chemotherapy
(vincrinstine, cyclophosphamide, prednisolone and doxorubicin)
(Lymphoma Study Group, 1979; Shimoyama et al, 1988) in 1978.
In that trial, consolidation chemotherapy using various regimens,
including VEMP (vindesine, cyclophosphamide, methotrexate and
prednisolone) and VQEP (vindesine, carbazilquinone, cyclophos-
phamide and prednisolone), was planned to continue monthly for
at least 2 years. In our pilot study of six advanced and/or non-
resectable PGL patients treated with a VEPA-like regimen, a
complete response was observed in 50% and partial response in
17% ofthe patients (Takenaka et al, 1982).
To avoid the problems associated with the interpretation of the
wide variation in results obtained using different treatment
approaches inretrospective studies, we began aprospective trial of
combined surgery and chemotherapy for the treatment of PGL
(stage II) patients in 1978. The results are presented here.
PATIENTS AND METHODS
Patients
Sixty-seven patients were diagnosed as having PGL [defined
according to the modified criteria of Dawson (1961)] and 61 of
these patients (91%) underwent gastrectomy at the NCC Hospital
between July 1978 and December 1993. Twenty-nine patients
were diagnosed as having stage II disease according to the Ann
Arbor classification (Carbone et al, 1971). Of these patients, 25
agreed to enter into the trial.
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Table I Chemotherapy regimens administered to 25 patients with prmary
gastric lymphoma (stage 11) (1978-93)
Regimen
m-VEPA (every 28 days)
Vincristine
Endoxan (cyclophosphamide)
Prednisolone
Doxorubicin
VEMP (every 28 days)
Vindesine
Endoxan (cyclophosphamide)
Methotrexate
Prednisolone
VQEP (every 28 days)
Vindesine
Carbazilquinone
Endoxan (cyclophosphamide)
Prednisolone
1 me
350
30n
30n
2 mc
350
30n
30n
Staging
The clinicopathological stages of the 25 patients were diagnosed
Dose Route Days given and determined from the physical, radiological, endoscopical,
surgical and histopathological findings, including routine haema-
g m-2 i.v. 1, 8 tological and chemical examinations, bone marrow aspiration and
mg m-2 i.v. 1, 8 renal function test. The examinations used forthe staging varied at
ng m-2 p.o. 1-3, 8-10 times. Chestradiography and gastrointestinal contrastradiography
ng m-2 i.v. 1 were performed in all 25 patients; 67Ga scintigraphy of the total
body was performed in 23 patients and ultrasonography of the
g m-2 i.v. 1, 8 abdomen in 24 patients. Only seven patients in this series were
rMgm-2 i.v. 1, 8 examined by computerized tomography (CT). Consequently, ngm-2 i.o 1-3,8-10 patients were staged according to the original Ann Arbor classifi-
cation in the present study.
2 mgm-2
2 mgm-2
350 mg m-2
30 mgm-2
i.v.
i.v.
i.v.
P.O.
1, 8
1, 8
1, 8
1-3, 8-10
A
100
-i ,o)
2!
cn
50
.A.4JJLJAZ1..J
Chemotherapy
Chemotherapy according to the modified-VEPA (m-VEPA)
regimen was given as post-operative chemotherapy for about 1
year to all 25 of these stage II PGL patients with no evidence of
macroscopic residual disease (Table 1).
Additional chemotherapy ('consolidation' chemotherapy),
according to the VEMP regimen or the VQEP regimen was given
mainly to patients with no evidence ofactive disease after about 1
year ofpost-operative chemotherapy (Table 1).
100
50
0-
cn
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Figure 1 Overall survival curve (A) and disease-free survival curve (B) in 25
pnmary gastric lymphoma (stage 11) patients treated with gastrectomy
followed by chemotherapy. Tick marks indicate the date on which the patient
was last examined (alive)
Histopathology
All biopsy and surgical specimens, originally diagnosed according
to the Working Formulation (WF) of non-Hodgkin's lymphoma
(The Non-Hodgkin's Lymphoma Pathologic Classification
Project, 1982).
In addition, surgical specimens were re-evaluated ifhistological
features indicating an origin from mucosa-associated lymphoid
tissue (MALT) (Isaacson et al, 1983) were present and classified
into the following three groups: MALT lymphoma with orwithout
areas of large-cell cytology (low-grade MALT); diffuse large-cell
lymphoma with areas showing MALT features (high-grade
MALT); and diffuse large-cell lymphoma without MALT features
(non-MALT).
Statistics
Survival was calculated from the date ofsurgery to the last follow-
up or to the date of death. The last follow-up date was August
1996. Survival curves were plotted using the Kaplan-Meier
method (Kaplan and Meier, 1958).
RESULTS
Surgery and clinicopathological findings
Radical tumour resection with curative intent was performed in 61
consecutive patients with PGL. Of the 29 patients diagnosed as
having stage II disease, three patients elected to be treated by
second-generation chemotherapy as post-operative chemotherapy
and another patient refused adjuvant treatment.
The remaining 25 PGL (stage II) patients were enrolled in the
study (Table 2). Fourteen patients were women and 11 were men.
Their ages atpresentation ranged from 36 to 82 (median 56) years.
In 4 of the 25 patients, partial gastrectomy was performed; total
gastrectomy was performed in the other 21.
The size ofthe primary tumour varied from 3.4 to 20.0 (median
10.5) cm in the maximum diameter. Twenty patients were classi-
fied as having diffuse large cell lymphoma, three as mixed small
and large cell, one as diffuse small cleaved cell and one as follic-
ular predominantly large cell lymphoma. All patients were classi-
fied as having intermediate-grade lymphoma (WF-system).
Three of the 22 re-evaluated patients were classified as having
low-grade MALT lymphoma and 13 patients as having high-grade
MALT lymphoma. The remaining six patients were classified as
having non-MALT lymphoma.
The depth of tumour infiltration into the gastric wall was the
submucosa in seven patients, muscularis propria in five, subserosa
in five and serosa without the involvement of adjacent organs in
eight.
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Table 2 Patients with stage 11 primary gastric lymphoma
Patient Sex/ Working MALT Gastrectomy Size Tumour Node Resection Post-operative Additional Relapse Survival Status
number Age formulation grade (cm) depth invasion margin chemotherapy chemotherapy (months) (months)
(courses) (courses)
1 M/41 DL High Total 14.0 S 8/33 + (aw) 12 8 - 203 A
2 F/36 DL NE Total 7.0 SS 1/55 - 11 10 - 170 A
3 M/73 DL NE Total 14.0 S 6/57 - 12 9 - 167 A
4 M/41 DL NE Partial 4.8 P M 4/68 - 14 6 - 127 A
5 M/72 DL High Total 12.5 SM 19/38 - 3 - 6 8 D
6 F/44 DL None Total 8.0 P M 1/30 - 13 11 - 120 A
7 F/55 DL None Partial 9.0 S 1/29 - 15 10 - 121 A
8 M/51 DL High Total 14.0 P M 3/32 - 12 12 - 113 A
9 F/51 DL None Total 14.0 P M 3/36 - 12 12 - 109 A
10 M/44 DL High Total 13.0 SS 1/34 - 12 11 - 102 A
11 F/65 DL High Total 15.0 SM 1/55 - 14 8 - 100 A
12 Ff76 DL None Partial 6.0 S 3/16 - 13 9 - 29 D*
13 M/59 DL High Total 13.5 S 10/104 - 12 14 - 94 A
14 F/64 DSC High Total 3.4 S M 7/89 - 4 - 15 35 D**
15 F/58 DL None Total 10.5 SS 4/62 - 4 - - 57 D*
16 F/47 DL High Total 6.0 SM 13/93 - 12 7 - 75 A
17 M/53 DM High Total 20.0 S 13/78 - 12 10 - 79 A
18 F/82 DL Low Total 10.5 P M 4/81 - 10 10 - 70 A
19 M/49 FL None Total 6.0 S M 2/44 - 3 - - 54 A
20 F/73 DM Low Total 10.5 S 5/123 - 11 - - 55 A
21 M/59 DM High Total 11.0 SS 1/91 - 12 - - 48 A
22 F/65 DL Low Total 15.0 S 3/64 - 10 6 - 34 A
23 M/56 DL High Total 13.0 S M 2/33 + (ow) 11 - - 47 A
24 F/57 DL High Partial 8.0 S M 1/85 - 12 - - 36 A
25 F/54 DL High Total 6.6 SS 5/39 - 10 - - 26 A
DL, diffuse large cell; DSC, diffuse small cleaved cell; DM, diffuse mixed small and large cell; NE, not evaluated; FL, follicular predominantly large cell; SM,
submucosa; PM, muscularis propria, SS, subserosa; S, serosa; A, alive; D, died of malignant lymphoma (ML); D, died of other than ML, D* died of ML + other.
The number of lymph nodes involved ranged from 1 to 19
(median 3). In two patients, there was microscopic involvement of
the resection margin with lymphoma cells.
Chemotherapy and prognosis
Twenty-four patients were treated with m-VEPA and one patient
was treated with the same regimen excluding doxorubicin because
ofher advanced age (82 years).
Twenty-one of the 25 patients completed the post-operative
chemotherapy (m-VEPA), which ranged from 10 to 15 courses
(median 12 courses). Three out offive patients who received more
than 12 courses of m-VEPA were administered reduced doses of
doxorubicin, which ranged from 90% to 80% per course,
according to the judgement of the attending physicians. The
remaining two patients were treated with reduced doses (90% and
85%) of vincristine and doxorubicin per course because of their
potential for adverse effects. Consequently, one to three courses of
m-VEPA were supplementally administered to these patients. Of
these 21 patients, 16 received consolidationchemotherapy ranging
from 6 to 14 (median 10) courses; the other five patients refused
consolidation chemotherapy. One patient was treated with 14
courses of consolidation chemotherapy by the judgement of his
doctor.
Four of the 25 patients could not complete even the projected
post-operative chemotherapy. There was one death from tumour
recurrence 8 months after surgery. In this patient, chemotherapy
was terminated after only three courses of m-VEPA because of
severe liver dysfunction induced by reactivated Schistosomiasis
japonica. In the other three patients, treatment was limited to three
or four courses of m-VEPA at the patients' request. One patient
with tumourrelapse died in an accident and anotherpatient died of
pulmonary disease without any evidence of lymphoma. The
remaining patient has continued in complete remission 54 months
after surgery.
The median overall survival rate has not yet been reached
between 26 and 203 months after gastrectomy. The overall
survival rate for all 25 patients was 81.6% at 10 years, including
all causes of death (Figure IA). Of interest is the finding that the
disease-free survival period showed a long plateau (excluding the
two patients with early treatment failure or accidental death). The
disease-free survival rate was 92.0% at 10 years (Figure iB). Of
the 21 patients who received more than ten courses ofpost-opera-
tive chemotherapy, none developed recurrence.
Toxicity and complications
No major surgical complications, such as operative mortality,
bleeding and dumping syndrome disturbing daily lives or treat-
ment-related death after chemotherapy, were observed in this
series. However, loss ofweight (about 10%) occurred in almost all
ofthe patients during chemotherapy.
Chemotherapy was complicated in two patients by moderate
peripheral neuropathy; their vincristine doses were reduced. Three
patients developed a reactivation of chronic hepatitis B or C virus
because ofchemotherapy; their treatment was stopped for several
weeks. Two documented infections were observed in two
patients: one patient developed mycoplasma pneumonia and
the other enterococcal septicaemia. Although leucocytopenia
(<2.0x 103p1l-1) was observed during the post-operative or
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consolidation chemotherapy in 8 ofthe 25 patients, no thrombocy-
topenia (< 10 x 104 l-') was observed.
DISCUSSION
Of the various modalities used to treat PGL, surgical resection is
the most commonly used initial treatment. The role of surgery in
the management ofPGL is to ensure an accurate histopathological
diagnosis, reduce tumour bulk, relieve symptoms and prevent
bleeding and perforation. Although the actual frequency of
chemotherapy-related bleeding or perforation is not clear, the
frequency of these complications in unresected patients with
gastrointestinal lymphoma reported previously varies from 0% to
20% (Brooks et al, 1983; Gobbi et al, 1984; Rosenfelt et al, 1980).
Another important aspect of surgery is tumour staging, and many
authors have reported that this is the most important prognostic
factor affecting survival (Lim et al, 1977; Shiu et al, 1982; Brooks
et al, 1983; Dragosics et al, 1985; Hockey et al, 1987) Any addi-
tional treatment is based on the pathological stage, and surgical
exploration with gastrectomy is the only means ofachieving this.
Favourable results for stage I and II PGL using surgical resec-
tion followed by chemotherapy have been reported by several
authors (Paulson et al, 1983; Sheridan et al, 1985; Shepherd et al,
1988; Bellesi et al, 1989; Pasini et al, 1994), but these reports
failed to discriminate between stage I and stage II disease. In the
present study, we focused on stage II PGL because the results
obtained from a previous study (Takenaka et al, 1981) suggested
that: (a) stage I PGLis curedby gastrectomy alone; and (b) stage II
PGL relapses occasionally without adjuvant chemotherapy.
In ourhospital (during the same period as our stage II study), 27
consecutive stage I PGL patients were treated by total gastrectomy
alone. After 14-205 (median 99) months of follow-up, none has
shown any sign ofrelapse (unpublished data). These results concur
with the hypothesis that post-operative chemotherapy is not
necessary for stage I PGL patients (Takenaka et al, 1981; Paulson
et al, 1983).
Discrimination between stage II, and stage II2 using Musshoff's
staging system (Musshoff, 1977) was difficult in this study,
because established staging procedures were not used. However,
the results of the present study show that stage II PGL is curable
with well-planned chemotherapy after surgical resection.
Considering that a definite prognostic difference exists between
stage II, and stage "2patients (Dragosics et al, 1984), further study
is necessary to develop the best treatment modalities for stage 11,
and stage 112 determined by established staging procedures.
The present adjuvant chemotherapy regimen consisting of
post-operative chemotherapy with m-VEPA and consolidation
chemotherapy with VQEP or VEMP requires about 2 years for
completion. It is important to determine whether consolidation
chemotherapy is necessary for the prevention of recurrence. No
relapses were observed in the present study between 20 and 49
months among the five patients who refused consolidation
chemotherapy. Adjuvant chemotherapy regimens for PGL stage II
patients should be studied further and selected with consideration
of both treatment duration and effectiveness. Considering a
previous report on aggressive lymphoma (Fisher et al, 1993), we
suggest that the standard CHOP regimen is a valid form of
chemotherapy. We began an adjuvant chemotherapy study ofPGL
stage IIpatients using aCHOPregimen in November 1994. Severe
toxicities and relapses have not been observed to date.
To preserve the stomach, patients with localized PGL have been
treated with chemotherapy, radiotherapy and chemotherapy plus
radiotherapy. Burgers et al (1988) reported a 4-year disease-free
survival rate of 83% in 24 patients with stage I PGL treated with
whole abdominal radiotherapy with a gastric bed boost. Maor et al
(1990) reported a 5-year disease-free survival rate of 62% in 34
patients with stage I and II PGL treated with combination
chemotherapy and involved-field radiotherapy. These results are
not superior to our survival rate and disease-free survival rate
obtained by surgery plus adjuvant chemotherapy. Although combi-
nation chemotherapy as an initial treatment has been shown to be
useful in PGLs (Maor et al, 1984; Salles et al, 1991), data are
not available concerning the treatment of localized PGL with
chemotherapy alone.
Helicobacter pylori is present in 92% of gastric low-grade
MALT lymphomas (Wotherspoon et al, 1991). After the eradica-
tion ofH. pylori with antibiotics, five out of six low-grade gastric
B-cell MALT lymphomas showed no evidence of lymphoma
(Wotherspoon et al, 1993). However, the patients enrolled in the
present study were not examined for H. pylori infection; that is a
future task.
In addition, most low-grade MALT lymphomas are at stage IE;
a minority are at stage II,, according to Isaacson and Norton
(1994). Only three (14%) of our stage II patients had low-grade
MALT lymphoma. Interestingly, ofour 22 stage I patients re-eval-
uated histologically, 16 cases were classified as low-grade MALT
lymphoma, two as high-grade and four as non-MALT lymphoma
(unpublished data).
According to our experience, about half of the localized PGL
cases are stage I and the other half are stage II. If an accurate
discrimination among stage I, stage III and stage II2 is possible by
non-invasive or non-surgical procedures, e.g. endoscopic ultra-
sonography or CT, radiotherapy instead of surgery for stage I and
chemotherapy for stage III and stage 112 may be indicated as an
initial induction therapy.
Localized PGL should be studied prospectively regarding the
relationships among histological grade, infection of H. pylori,
treatment modality and prognosis.
Although our treatment results for stage II PGL should be
assessed by multicentre prospective studies, we conclude for the
present that patients with localized PGL should undergo surgical
resection if possible, and, for patients found to have stage II
disease, adjuvant chemotherapy offers the best chance of cure or
long-term survival.
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